Journal
CLINICAL INFECTIOUS DISEASES
Volume 50, Issue 1, Pages 73-76Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/648727
Keywords
-
Categories
Funding
- US Agency for International Development-Centers for Disease Control and Prevention interagency [GHN-T-00-06-00001-00]
- National Institutes of Health [F32GM085945]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM085945] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Post-kala-azar dermal leishmaniasis (PKDL) occurs after kala-azar treatment and acts as a durable infection reservoir. On the basis of active case finding among 22,699 respondents, 813 (3.6%) had had kala-azar since 2002, of whom 79 (9.7%) developed PKDL. Eight additional patients with PKDL had no history of kala-azar. Annual kala-azar incidence peaked at 85 cases per 10,000 person-years in 2004 and fell to 46 cases per 10,000 person-years in 2007, but PKDL incidence rose from 1 case per 10,000 person-years in 2002-2004 to 21 cases per 10,000 person-years in 2007. The rising PKDL incidence threatens the regional visceral leishmaniasis elimination initiative and underscores the urgent need for more effective PKDL diagnosis and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available